Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
latent TB
latent infection
pharmacokinetics-pharmacodynamics
population pharmacokinetics
rifapentine
translational pharmacology
tuberculosis
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
17 11 2021
17 11 2021
Historique:
pubmed:
5
10
2021
medline:
15
12
2021
entrez:
4
10
2021
Statut:
ppublish
Résumé
Rifapentine has facilitated treatment shortening for latent tuberculosis infection (LTBI) in combination with isoniazid once weekly for 3 months (3HP) or daily for 1 month (1HP). Our objective was to determine the optimal rifapentine dose for a 6-week monotherapy regimen (6wP) and predict clinical efficacy. Rifapentine and isoniazid pharmacokinetics were simulated in mice and humans. Mouse lung CFU data were used to characterize exposure-response relationships of 1HP, 3HP, and 6wP and translated to predict clinical efficacy. A 600-mg daily dose for 6wP delivered greater cumulative rifapentine exposure than 1HP or 3HP. The maximum regimen effect (
Identifiants
pubmed: 34606336
doi: 10.1128/AAC.01705-21
pmc: PMC8597776
doi:
Substances chimiques
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Rifampin
VJT6J7R4TR
rifapentine
XJM390A33U
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0170521Subventions
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI111992
Pays : United States
Organisme : HHS | National Institutes of Health (NIH)
ID : 1P30AI094189
Organisme : HHS | National Institutes of Health (NIH)
ID : R01-AI111992
Organisme : NIGMS NIH HHS
ID : T32 GM007546
Pays : United States
Organisme : FDA HHS
ID : U18 FD004004
Pays : United States
Organisme : HHS | U.S. Food and Drug Administration (FDA)
ID : U18-FD004004
Organisme : NIGMS NIH HHS
ID : T32 GM007175
Pays : United States
Organisme : HHS | Centers for Disease Control and Prevention (CDC)
ID : CDC 09FED07950
Références
Clin Infect Dis. 2015 Aug 15;61(4):527-35
pubmed: 25904367
Am J Respir Crit Care Med. 2006 Jul 1;174(1):94-101
pubmed: 16574936
BMJ. 2018 Aug 23;362:k2738
pubmed: 30139910
Annu Rev Immunol. 2013;31:475-527
pubmed: 23516984
Am J Respir Crit Care Med. 2009 Dec 1;180(11):1151-7
pubmed: 19729664
Antimicrob Agents Chemother. 2014 Jun;58(6):3035-42
pubmed: 24614383
Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):494-7
pubmed: 1736764
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036
pubmed: 28803492
BMJ. 2019 Oct 24;367:l5770
pubmed: 31649096
Am J Respir Crit Care Med. 2011 Sep 15;184(6):732-7
pubmed: 21659613
N Engl J Med. 2019 Mar 14;380(11):1001-1011
pubmed: 30865794
Am J Respir Crit Care Med. 2020 Sep 15;202(6):866-877
pubmed: 32412342
Antimicrob Agents Chemother. 2010 Aug;54(8):3390-4
pubmed: 20516273
Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v
pubmed: 26260821
Clin Pharmacol Ther. 2017 Aug;102(2):321-331
pubmed: 28124478
J Clin Med. 2019 Jun 06;8(6):
pubmed: 31174321
Am Rev Respir Dis. 1978 Jun;117(6):991-1001
pubmed: 666111
Antimicrob Agents Chemother. 2007 Nov;51(11):3781-8
pubmed: 17724157
Antimicrob Agents Chemother. 2003 Jul;47(7):2118-24
pubmed: 12821456
Br J Clin Pharmacol. 2011 Jul;72(1):51-62
pubmed: 21320152
N Engl J Med. 2018 Aug 2;379(5):440-453
pubmed: 30067931
J Antibiot (Tokyo). 1984 Sep;37(9):1066-75
pubmed: 6501103
JAMA. 2016 Sep 6;316(9):931-3
pubmed: 27599327
N Engl J Med. 2011 Dec 8;365(23):2155-66
pubmed: 22150035
Eur J Pharm Sci. 2013 Apr 11;49(1):33-8
pubmed: 23395915
Chest. 2010 Feb;137(2):401-9
pubmed: 19793865